Healthcare

For Novonix Limited (ASX:NVX), 21 May 2026 brought a modest but meaningful uptick of 2.27% to AUD 0.22 — a move that on its own might appear unremarkable, but which sits against a backdrop of consequential corporate developments that have accumulated through late April …

Based on available market data, Clarity Pharmaceuticals Ltd. shares may be rising on a combination of stock-specific positioning and broader sector sentiment. The move could reflect renewed interest in ASX biotech names as risk appetite improves. While there is no confirmed corporate news disclosed …

Vitrafy Life Sciences Ltd (ASX:VFY) ended lower on 21 May 2026, slipping 6.02% to A$2.34. The decline placed the stock among the weaker performers on the ASX, although the move occurred in extremely thin trading conditions.

CSL Limited (ASX:CSL) has entered a critical phase as investors reassess the company’s growth trajectory following a major downgrade to FY26 guidance, large-scaleImpairmentannouncements, and an ongoingLeadershiptransition. Once regarded as one of Australia’s most dependable healthcare growth stories, CSL has seen its share price come …

AFT Pharmaceuticals Ltd (ASX:AFP) has reported a positive financial performance for the year ended 31 March 2026, highlighting recordEarnings, double-digit revenue growth, and continued international expansion across key pharmaceutical markets.

Argenica Therapeutics Ltd (ASX:AGN) shares increased 1.48% to AUD 0.14 during the afternoon session on 21 May 2026 after the biotechnology company announced favourable results from a key FDA-requested safety study linked to its lead drug candidate, ARG-007. Despite today’s gain, the stock remains …

Island Pharmaceuticals Ltd (ASX:ILA) shares moved higher during the afternoon session on 21 May 2026 after the company announced the appointment of former BioCryst Pharmaceuticals executive Raymond Taylor to support the development of its antiviral candidate Galidesivir.